IP Library Granted Patent US 10,029,083
Granted Patent B2
US 10,029,083 · App. 15/378,109 · Granted Jul 24, 2018

Medical devices for delivery of siRNA

Inventor: Russell Frederick Ross (Atlanta, GA)
Assignee: Kimberly-Clark Worldwide, Inc.
A61M37/0015C12N15/113A61M2037/0023A61M2037/0038A61M2037/0053A61M2037/0061C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,029,083
App. No.
15/378,109
Granted
Jul 24, 2018
Kind
B2
Abstract

Medical devices that incorporate siRNA are provided. In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be incorporated on devices. The pattern including nanostructures may be formed on the surface of the microneedles.

Claims (33)

1. A device for delivery of an siRNA construct across a dermal barrier, the device comprising:

a microneedle and a plurality of nanostructures fabricated on a surface of the microneedle to project outward from the surface of the microneedle, the nanostructures being arranged in a predetermined pattern, wherein at least a portion of the nanostructures have a cross-sectional dimension of less than 500 nanometers and greater than 5 nanometers, a height of from 10 nanometers to 1 micrometer and an aspect ratio of from 0.2 to 5, and wherein the microneedle further contains a channel; and

a reservoir that is in fluid communication with the channel of the microneedle and that contains an siRNA construct.

2. The device of claim 1 , wherein the pattern further includes microstructures, wherein the nanostructures have a cross-sectional dimension smaller than the microstructures.

3. The device of claim 2 , further comprising second nanostructures having a cross-sectional dimension less than the cross-sectional dimension of the microstructures and greater than the cross-sectional dimension of the first nanostructures.

4. The device of claim 1 , wherein at least a portion of the nanostructures have a cross-sectional dimension of less than 400 nanometers and greater than 10 nanometers.

5. The device of claim 1 , wherein at least a portion of the nanostructures have a center-to-center spacing of from 50 nanometers to 1 micrometer.

6. The device of claim 1 , wherein at least a portion of the nanostructures have a height of from 100 nanometers to 700 nanometers.

7. The device of claim 1 , wherein at least a portion of the nanostructures have an aspect ratio of from 0.5 to 3.5.

8. The device of claim 1 , wherein the siRNA agent includes a duplexed region of between 20 and 30 pairs.

9. The device of claim 1 , at least one strand of the siRNA including a 3′ overhang of two or three nucleotides.

10. The device of claim 1 , the siRNA agent comprising additional nucleotides or nucleotide analogue.

11. The device of claim 1 , wherein the siRNA agent comprises a nucleotide sequence that is identical to a portion of a targeted gene.

12. The device of claim 1 , wherein the siRNA agent includes insertions, deletions, or single point mutations compared to a portion of a targeted gene.

13. The device of claim 1 , wherein the siRNA agent is a single strand siRNA.

14. The device of any of claim 1 , wherein the siRNA comprises a ligand tethered to the siRNA.

15. The device of claim 1 , wherein the siRNA agent is incorporated into a delivery vehicle.

16. The device of claim 1 ; wherein the siRNA construct comprises a vector.

17. The device according to claim 1 , wherein the pattern has a fractal dimension of greater than 1 and up to 5.

18. The device according to claim 1 , wherein at least a portion of the nanostructures have a cross-sectional dimension of from 100 to 300 nanometers.

19. The device according to claim 1 , wherein the nanostructures have approximately the same cross-sectional dimension.

20. The device according to claim 1 , wherein the ratio of the cross sectional dimension of two adjacent nanostructures to the center-to-center spacing between those two structures is between 1:1 and 1:4.

21. The device according to claim 1 , wherein at least a portion of the nanostructures have an equidistant spacing.

22. The device according to claim 1 , wherein at least a portion of the nanostructures are in the form of pillars.

23. The device according to claim 1 , wherein the channel has a cross-sectional dimension of from 1 to 100 micrometers.

24. The device according to claim 23 , wherein the channel has a length of from 10 to 800 micrometers.

25. The device according to claim 1 , wherein the device contains a microneedle array that contains the microneedle.

26. The device according to claim 25 , wherein the array contains a base having an aperture, wherein the aperture is in at least partial alignment with the channel of the microneedle.

27. The device according to claim 26 , wherein the reservoir is attached to a substrate upon which the array is located.

28. The device according to claim 26 , wherein the reservoir is removably connected to the array.

29. A method for delivering an siRNA construct across a dermal barrier, the method comprising:

penetrating the stratum corneum with a microneedle having a surface on which a plurality of nanostructures are fabricated in a predetermined pattern to project outward from the surface of the microneedle, wherein at least a portion of the nanostructures have a cross-sectional dimension of less than 500 nanometers and greater than 5 nanometers, a height of from 10 nanometers to 1 micrometer and an aspect ratio of from 0.2 to 5, and, wherein the microneedle further contains a channel

transporting an siRNA construct from a reservoir through the channel of the microneedle and across the stratum corneum.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2018
From: ROSS, RUSSELL FREDERICK
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 047385/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2018
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 046899/0689 →
Continuity (4)
Continuation 13641502
Provisional Application 61416057 · Nov 22, 2010
Provisional Application 61328723 · Apr 28, 2010
Related Publication 20170157381A1 · Jun 8, 2017
Cited By (1)
US 12,280,540